Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.78 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.74 |
| ▸ | HTR3B | O95264 | 5/20 | 0.74 |
| ▸ | HTR3A | P46098 | 5/20 | 0.74 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.74 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225472 | 1.00 | CHRNA7 (0.78) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3216388 | 1.00 | CHRNA7 (0.78) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL7278119 | 0.98 | CHRNA7 (0.76) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL18704540 | 0.98 | CHRNA7 (0.76) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL372943 | 0.94 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2230266 | 0.91 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3499803 | 0.91 | CHRNA7 (0.74) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL373028 | 0.88 | CHRNA7 (0.70) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL373736 | 0.88 | CHRNA7 (1.00) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4205298 | 0.88 | CHRNA7 (0.71) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850120-A | Preparation method of alcohol alpha-carbon hydrogen bond alkylated compound | 浙江工业大学 | 2023-03-28 | — | — | CN | claimed |
| US-5236931-A | Treating anxiety, psychosis, cognitive dysfunction, migrane, cluster headache, trigeminal neuralgia emesis and impaired gastric motility | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-08-17 | — | — | US | claimed |
| EP-0190920-B1 | METHOD OF ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY WITH ARYLAMIDO (AND ARYLTHIOAMIDO)AZABICYCLOALKANES | SYNTHELABO (FR) | 1993-05-05 | — | — | EP | claimed |
| EP-0327335-B1 | ARYLAMIDO(AND ARYLTHIOAMIDO)-AZABICYCLOALKANES FOR ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY | SYNTHELABO (FR) | 1992-10-14 | — | — | EP | claimed |
| US-4863919-A | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-09-05 | — | — | US | claimed |
| EP-0327335-A1 | Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency | SYNTHELABO (FR) | 1989-08-09 | — | — | EP | claimed |
| EP-0190920-A2 | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)azabicycloalkanes | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | claimed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | claimed |
| JP-2256616-A | — | — | None | — | — | JP | disclosed |
| JP-2104529-A | — | — | None | — | — | JP | disclosed |
| CN-115850120-A | Preparation method of alcohol alpha-carbon hydrogen bond alkylated compound | 浙江工业大学 | 2023-03-28 | — | — | CN | disclosed |
| US-20110178118-A1 | PALONOSETRON FOR THE TREATMENT OF CHEMOTHERAPY INDUCED EMESES | HELSINN HEALTHCARE SA (CH) | 2011-07-21 | — | — | US | disclosed |
| EP-2344636-A2 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | Howard Hughes Medical Institute (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2258367-A2 | Use of palonosetron for treating post-operative nausea and vomiting | Helsinn Healthcare S.A. (CH) | 2010-12-08 | — | — | EP | disclosed |
| EP-0202062-A2 | Quinuclidine derivatives | BEECHAM GROUP PLC (GB) | 1986-11-20 | — | — | EP | disclosed |
| EP-0190915-A2 | Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2]octan-3-yl) aminobenzamides | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | disclosed |
| EP-0190920-A2 | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)azabicycloalkanes | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | disclosed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4593034-A | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178118-A1 | PALONOSETRON FOR THE TREATMENT OF CHEMOTHERAPY INDUCED EMESES | HTR3A, HTR3C, HTR3B | CHRNA7 409/4885HTR3E 4/4885HTR3B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.